Abstract: The invention relates to methods of producing a plant with delayed senescence comprising inducing at least one nucleotide deletion, insertion or substitution into at least one copy of a gene encoding deoxyhypusine synthase (DHS) in the plant, wherein the nucleotide deletion, insertion or substitution decreases the activity of DHS encoded by the gene in the plant. The invention also relates to plants produced by the methods and progeny thereof.

Abstract: The present application relates to methods for the isolation of EVs from a sample containing EVs, the method comprising: (i) contacting the sample with one or more polyethylenimines to form an EV-polyethylenimine complex; and (ii) separating the EV-polyethylenimine complex from the sample. Also included in the application are kits for performing the methods for isolating EVs and methods of diagnosis and therapy using the EVs isolated using the described methods.

Abstract: The invention relates to methods of producing a plant with delayed senescence comprising inducing at least one nucleotide deletion, insertion or substitution into at least one copy of a gene encoding deoxyhypusine synthase (DHS) in the plant, wherein the nucleotide deletion, insertion or substitution decreases the activity of DHS encoded by the gene in the plant. The invention also relates to plants produced by the methods and progeny thereof.

Abstract: The invention relates to methods of producing a plant with delayed senescence comprising inducing at least one nucleotide deletion, insertion or substitution into at least one copy of a gene encoding deoxyhypusine synthase (DHS) in the plant, wherein the nucleotide deletion, insertion or substitution decreases the activity of DHS encoded by the gene in the plant. The invention also relates to plants produced by the methods and progeny thereof.

Abstract: In some embodiments a window treatment securement device may include a first elongated member having a first mounting plate. A first frame stake may be coupled to the first elongated member, and a first receiving slot may be coupled to the first mounting plate. The first elongated member may optionally be coupled to a second elongated member having a second mounting plate. A second frame stake may be coupled to the second elongated member, and a second receiving slot may be coupled to the second mounting plate. The device may be affixed to an object, such as walls and window trim, and a window treatment may be secured to the device thereby securing the window treatment to the object.

Abstract: In some embodiments a window treatment securement device may include a first elongated member having a first mounting plate. A first frame stake may be coupled to the first elongated member, and a first receiving slot may be coupled to the first mounting plate. The first elongated member may optionally be coupled to a second elongated member having a second mounting plate. A second frame stake may be coupled to the second elongated member, and a second receiving slot may be coupled to the second mounting plate. The device may be affixed to an object, such as walls and window trim, and a window treatment may be secured to the device thereby securing the window treatment to the object.

Abstract: An oligouronate is used in the treatment or prevention of cancer as an anticancer agent. The oligouronate is effective against cancer itself, and as a drug delivery tool which improves or promotes the delivery of another anticancer agent, such as a chemotherapy drug or immunotherapeutic agent. Thus, the oligouronate is used in cancer prevention or treatment alone or in combination with one or more other anticancer agents.

Abstract: The present invention relates to the treatment of multiple myeloma in a human subject comprising administering lenadlidomide in combination with a vector which expresses a human eIF-SAI which is unable to be hypusinated and an siRNA which targets eIF-SAI. In some embodiments, the lenalidomide is administered simultaneously with the vector and the siRNA while in some embodiments the lenalidomide is administered at a time that is different from when the vector and the siRNA are administered. In some embodiments, the lenalidomide is administered orally and the vector and the siRNA are administered intraveneously.

Abstract: A composition useful in gene therapy and a method of treatment to effect gene therapy is provided. In particular, a pharmaceutical composition comprising a nonimmunogenic net polyanionic oligosaccharide, such as an oligouronate, associated with a particulate complex of an anionic nucleic acid material and a cationic macromolecule, optionally together with at least one pharmaceutical carrier or excipient, is provided.

Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock.

Abstract: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.

Abstract: The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (FG) of at least 0.80, a mannuronate fraction (FM) of no more than 0.20, and having at least 95% mole with a degree of polymerization less than 20. The composition may be used in a method of treatment which comprises administering the composition to a mucosal surface in a human or non-human vertebrate subject.

Abstract: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific and DHS useful in such methods.

Abstract: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide. The present invention also relates to a truncated form of eIF-5A1 that is useful for inducing apoptosis and killing of cells, especially cancer cells in a mammal.

Abstract: A method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method includes application to a mucosal surface in the tract in the subject of an effective amount of a physiologically tolerable oligouronate. Related compositions containing physiologically tolerable oligouronates are also described.

Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.

Abstract: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.